X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6) 6
index medicus (6) 6
care and treatment (5) 5
female (5) 5
middle aged (5) 5
aged (4) 4
analysis (4) 4
chemotherapy (4) 4
hematology, oncology and palliative medicine (4) 4
immunohistochemistry (4) 4
male (4) 4
oncology (4) 4
tumors (4) 4
antibodies, monoclonal - administration & dosage (3) 3
antibodies, monoclonal - adverse effects (3) 3
article (3) 3
biomarkers (3) 3
cancer (3) 3
cancer therapies (3) 3
diagnosis (3) 3
lung neoplasms - pathology (3) 3
metastasis (3) 3
monoclonal antibodies (3) 3
patients (3) 3
prospective studies (3) 3
risk factors (3) 3
anti-pd-l1 antibody avelumab (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
biomarkers, tumor - metabolism (2) 2
blockade (2) 2
breast-cancer (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
carcinomas (2) 2
clinical trials (2) 2
cytotoxicity (2) 2
disease-free survival (2) 2
drug dosages (2) 2
epidermal growth factor (2) 2
fatigue (2) 2
fatigue - chemically induced (2) 2
immunoglobulins (2) 2
immunotherapy (2) 2
kaplan-meier estimate (2) 2
lung cancer (2) 2
lung cancer, non-small cell (2) 2
lung cancer, small cell (2) 2
lung neoplasms - drug therapy (2) 2
medical colleges (2) 2
metastases (2) 2
nivolumab (2) 2
pd-l1 protein (2) 2
receptor, epidermal growth factor - metabolism (2) 2
response evaluation criteria in solid tumors (2) 2
safety (2) 2
studies (2) 2
tissue array analysis (2) 2
toxicity (2) 2
abdominal pain - chemically induced (1) 1
abridged index medicus (1) 1
acquired-resistance (1) 1
adolescent (1) 1
adult (1) 1
age (1) 1
aged, 80 and over (1) 1
amylases - blood (1) 1
antibodies (1) 1
antibodies - blood (1) 1
antibodies, monoclonal - immunology (1) 1
antibodies, monoclonal - pharmacokinetics (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - immunology (1) 1
antineoplastic agents - pharmacokinetics (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
aspartate aminotransferase (1) 1
aspartate aminotransferases - blood (1) 1
autoimmune diseases - chemically induced (1) 1
b7-h1 (1) 1
b7-h1 antigen - antagonists & inhibitors (1) 1
biomarkers, tumor - analysis (1) 1
biomarkers, tumor - antagonists & inhibitors (1) 1
biopsy (1) 1
blood (1) 1
blotting, western (1) 1
brazil (1) 1
cancer patients (1) 1
carcinoma (1) 1
carcinoma, merkel cell - drug therapy (1) 1
carcinoma, merkel cell - mortality (1) 1
carcinoma, merkel cell - pathology (1) 1
carcinoma, non-small-cell lung - enzymology (1) 1
carcinoma, non-small-cell lung - epidemiology (1) 1
carcinoma, non-small-cell lung - metabolism (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
carcinoma, non-small-cell lung - secondary (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 587 - 598
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 599 - 610
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 1, pp. 33 - 42
Summary Background Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study showed that the addition of cetuximab to first-line chemotherapy... 
Hematology, Oncology and Palliative Medicine | BREAST-CANCER | BIOMARKERS | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | ONCOLOGY | PROTEIN EXPRESSION | IN-SITU HYBRIDIZATION | CARCINOMAS | GENE AMPLIFICATION | ESTROGEN-RECEPTOR | III TRIAL | Immunohistochemistry | Lung Neoplasms - drug therapy | Up-Regulation | Prospective Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Patient Selection | Young Adult | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Vinblastine - analogs & derivatives | Aged, 80 and over | Biomarkers, Tumor - metabolism | Brazil | Adult | Female | Biomarkers, Tumor - antagonists & inhibitors | Cetuximab | Odds Ratio | Republic of Korea | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - enzymology | Risk Assessment | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Care and treatment | Patient outcomes | Oncology, Experimental | Research | Lung cancer, Non-small cell | Antineoplastic agents | Antimitotic agents | Cancer patients | Chemotherapy | Product development | Tumors | Cancer
Journal Article
Archives of Pathology and Laboratory Medicine, ISSN 0003-9985, 09/2013, Volume 137, Issue 9, pp. 1255 - 1261
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.